Disposition of eligible patients with Guillain-Barré Syndrome (GBS), by vaccination and infection exposure status^a and timing of diagnosis, Vaccine Safety Datalink, 2009–2011.

a26 cases had both prior exposures in the 1 through 141 days prior to GBS diagnosis. b2009–10 monovalent inactivated influenza vaccine or 2010–11 trivalent inactivated influenza vaccine. cMedically-attended respiratory, gastrointestinal, or unspecified viral infection. dFor cases with electronic diagnoses of CIDP (n = 9): median length between GBS diagnosis and first CIDP diagnosis: 51 days (interquartile range: 4, 81). eAlternative diagnoses included: transverse myelitis/myelitis (including post-viral or varicella zoster virus), acute disseminated encephalomyelitis, conversion disorder/functional component, viral illness, viral ataxia, viral myopathy, Charcot-Marie-Tooth disease, diabetic amyotrophy or myopathy, generalized vasculitis, vasculitis neuropathy, hereditary brachial neuropathy, Lyme meningitis, multiple cranial neuropathy, multiple sclerosis, sarcoid neuropathy, encephalomyopathy radiculitis, myasthenia gravis, steroid myopathy, paresis, polymyositis, and not specified.